Eric C. Peterson

ORCID: 0000-0002-1420-2346
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Monoclonal and Polyclonal Antibodies Research
  • Vascular Procedures and Complications
  • Protein purification and stability
  • Receptor Mechanisms and Signaling
  • Central Venous Catheters and Hemodialysis
  • Venous Thromboembolism Diagnosis and Management
  • Virus-based gene therapy research
  • Peripheral Artery Disease Management
  • Viral Infectious Diseases and Gene Expression in Insects
  • Neurotransmitter Receptor Influence on Behavior
  • CRISPR and Genetic Engineering
  • Intracranial Aneurysms: Treatment and Complications
  • Ocular Oncology and Treatments
  • Traumatic Brain Injury and Neurovascular Disturbances
  • Chemical Synthesis and Analysis
  • Transgenic Plants and Applications
  • Forensic Toxicology and Drug Analysis
  • Vascular Malformations Diagnosis and Treatment
  • Glycosylation and Glycoproteins Research
  • CAR-T cell therapy research
  • Epigenetics and DNA Methylation
  • HIV Research and Treatment
  • Neuroscience of respiration and sleep
  • Soft tissue tumor case studies
  • Corneal Surgery and Treatments

Neurological Surgery
2009-2024

University of Miami
2014-2024

University of Arkansas for Medical Sciences
2013-2023

Abound Bio (United States)
2020

University of Pennsylvania
2020

Children's Hospital of Philadelphia
2020

Florida Atlantic University
2020

Boca Raton Regional Hospital
2020

Thomas Jefferson University
2019

University of Pittsburgh Medical Center
2019

The control of cerebral blood flow is complex, and only beginning to be elucidated. Studies have identified three key regulatory paradigms. first pressure autoregulation, which maintains a constant in the face changing perfusion pressure. Flow-metabolism coupling refers brains ability vary match metabolic activity. An extensive arborization perivascular nerves also serves modulate flow, so-called neurogenic regulation. Central these paradigms are two cell types: endothelium astrocytes....

10.1155/2011/823525 article EN cc-by International Journal of Vascular Medicine 2011-01-01

The technological advances in mass spectrometry allow us to collect more comprehensive data with higher quality and increasing speed. With the rapidly amount of generated, need for streamlining analyses becomes apparent. Proteomics is known be often affected by systemic bias from unknown sources, failing adequately normalize can lead erroneous conclusions. To researchers easily evaluate compare different normalization methods via a user-friendly interface, we have developed "proteiNorm"....

10.1021/acsomega.0c02564 article EN cc-by ACS Omega 2020-09-30

Background The transradial approach (TRA) to endovascular procedures decreases access site morbidity and mortality in comparison with the traditional transfemoral technique (TFA). Despite its improved safety profile, there is a concern that TRA less favorable for neurointerventional require large coaxial systems manage small tortuous cerebral vessels. Objective To report our experience flow diverter placement treatment of unruptured aneurysms. Methods We performed retrospective review...

10.1136/neurintsurg-2018-014620 article EN Journal of NeuroInterventional Surgery 2019-01-22

Phthalates and other endocrine-disruptive chemicals are manufactured in large quantities for use as plasticizers commercial applications, resulting ubiquitous human exposure thus, concern regarding their toxicity. Innate defense against small molecule exposures is controlled part by the constitutive androstane receptor (CAR) pregnane X (PXR). The CAR gene undergoes multiple alternative splicing events CAR2 CAR3 variant receptors. Recent studies from our laboratory show that potently...

10.1093/toxsci/kfq394 article EN Toxicological Sciences 2011-01-12

When generating monoclonal antibodies (mAb) against small molecules, the chemical composition and molecular orientation of drug-like hapten on antigen is a crucial determinant. This especially important when attempting to discover therapeutic mAb drugs abuse (+)-methamphetamine [(+)-METH], (+)-amphetamine [(+)-AMP], related compound (+)-3,4-methylenedioxymethamphetamine [(+)-MDMA, plus isomer in racemic mixture known as MDMA or ecstasy]. The goal these studies was design synthesize...

10.1124/jpet.106.117150 article EN Journal of Pharmacology and Experimental Therapeutics 2007-04-23

Transradial artery access (TRA) for cerebrovascular angiography is increasing due to decreased site complications and overwhelming patient preference. While interventional cardiologists have reported up 10 successive TRA procedures via the same radial site, this first study examining use of repeat in neurointerventional procedures.1 METHODS: We reviewed our prospective institutional database all patients who underwent a transradial procedure between 2015 2019. Index were defined as performed...

10.1136/neurintsurg-2019-015438 article EN Journal of NeuroInterventional Surgery 2019-10-05

This study reports the synthesis of mercapto-hapten (S)-N-(2-(mercaptoethyl)-6-(3-(2-(methylamino)propyl)phenoxy)hexanamide [3, (+)-METH HSMO9] and its use to prepare METH-conjugated vaccines (MCV) from maleimide-activated proteins. MALDI-TOF mass spectrometry analysis MCV synthesized using 3 showed there was a high controllable epitope density on two different carrier In addition, produced substantially greater immunological response in mice than previous METH haptens, monoclonal antibody...

10.1021/jm2004943 article EN Journal of Medicinal Chemistry 2011-06-18

Chronic or excessive (+)-methamphetamine (METH) use often leads to addiction and toxicity critical organs like the brain. With medical treatment as a goal, novel single-chain variable fragment (scFv) against METH was engineered from anti-METH monoclonal antibody mAb6H4 (IgG, κ light chain, <i>K</i><sub>d</sub> = 11 nM) found have similar ligand affinity (<i>K</i><sub>d</sub> 10 specificity mAb6H4. The scFv (scFv6H4) cloned, expressed in yeast, purified, formulated naturally occurring mixture...

10.1124/jpet.107.134395 article EN Journal of Pharmacology and Experimental Therapeutics 2008-01-11

The chloroplast signal recognition particle consists of a conserved 54-kDa GTPase and novel 43-kDa chromodomain protein (cpSRP43) that together bind light-harvesting chlorophyll a/b-binding (LHCP) to form soluble targeting complex is subsequently directed the thylakoid membrane. Homology-based modeling cpSRP43 indicates presence two previously identified chromodomains along with third N-terminal chromodomain. Chromodomain deletion constructs were used examine role each in mediating distinct...

10.1074/jbc.m401600200 article EN cc-by Journal of Biological Chemistry 2004-08-03

In addition to addiction, the repeated use of (+)-methamphetamine [(+)-METH], (+)-amphetamine [(+)-AMP], or (±)-3,4-methylenedioxymethamphetamine ((±)-MDMA, commonly called ecstasy) can lead life-threatening medical problems including cardiovascular injury, severe depression, and psychosis. Currently, there are no specific pharmacotherapies treat these problems. this study, we report design synthesis two haptens, (S)-(+)-3-(9-carboxynonyloxy)methamphetamine (3a, (+)-METH MO10)...

10.1021/jm901134w article EN Journal of Medicinal Chemistry 2009-10-29

Current guidelines recommend restricting acetaminophen (APAP) use in patients with cirrhosis, but evidence to support that recommendation is lacking. Prior studies focused on pharmacokinetics (PK) of APAP cirrhosis did not rigorously examine clinical outcomes, sensitive biomarkers liver damage, or serum APAP‐protein adducts, which are a specific marker toxic bioactivation. Hence, the goal this pilot study was test effects regularly scheduled dosing well‐defined compensated group compared...

10.1002/hep4.1810 article EN cc-by-nc-nd Hepatology Communications 2021-08-25

Methamphetamine (METH) abuse is a worldwide threat, without any FDA approved medications. Anti-METH IgGs and single chain fragments (scFvs) have shown efficacy in preclinical studies. Here we report affinity enhancement of an anti-METH scFv for METH its active metabolite amphetamine (AMP), through the introduction point mutations, rationally designed to optimize shape hydrophobicity antibody binding pocket. The was measured using saturation technique. mutant scFv-S93T showed 3.1 fold 26 AMP....

10.1038/srep03673 article EN cc-by-nc-nd Scientific Reports 2014-01-14

Methamphetamine (METH) is a major drug threat in the United States and worldwide. Monoclonal antibody (mAb) therapy for treating METH abuse showing exciting promise understanding of how mAb structure relates to function will be essential future development these important therapies. We have determined crystal structures high affinity anti-(+)-METH therapeutic single chain fragment (scFv6H4, K(D)= 10 nM) derived from one our candidate complex with (+) stereoisomer another abused drug,...

10.1002/pro.244 article EN Protein Science 2009-09-16

Background: The management of severe traumatic brain injury (sTBI) patients with and without intact cerebral pressure autoregulation (CPA) varies markedly. Recent studies, analyzing beat-to-beat interactions between intracranial (ICP) systolic blood pressure, or transcranial Doppler velocity changes during a rapid drop in perfusion (CPP), suggest that CPA is disrupted after sTBI. We use computed tomography (CTP) to guide manipulation sTBI have found results differ this literature. present...

10.1097/ta.0b013e3181ae6e6d article EN Journal of Trauma and Acute Care Surgery 2009-11-01

Treatments specific to the medical problems caused by methamphetamine (METH) abuse are greatly needed. Toward this goal, we developing new multivalent anti-METH antibody fragment-nanoparticle conjugates with customizable pharmacokinetic properties. We have designed a novel single chain fragment an engineered terminal cysteine (scFv6H4Cys). Generation 3 (G3) polyamidoamine dendrimer nanoparticles were chosen for conjugation due their monodisperse properties and multiple amine functional...

10.1021/bc300204n article EN Bioconjugate Chemistry 2012-08-09

To address the need for effective medications to aid in treatment of methamphetamine (METH) abuse, we used a nanotechnology approach customize vivo behavior an anti-METH single chain antibody (scFv7F9Cys). Anti-METH scFv7F9Cys was conjugated dendrimer nanoparticles via polyethylene glycol (PEG) linker generate high-order conjugates termed dendribodies. We found that high affinity (KD = 6.2 nM) and specificity METH unchanged after nanoparticle conjugation. The dendribodies were administered...

10.1038/srep12060 article EN cc-by Scientific Reports 2015-07-10

Immunotherapy for treating illicit drug abuse is a rapidly advancing field. There are currently two major approaches to developing drug-specific immunotherapies: active and passive. Active immunotherapy involves conjugating drug-like hapten carrier protein using traditional immunization generate immune response in the patient. In contrast, passive utilizes preformed monoclonal antibodies. Whether generated by or delivered passively, antibodies act as pharmacokinetic antagonists binding...

10.1124/mi.9.3.5 article EN Molecular Interventions 2009-06-01

Introduction: An active metabolite of buprenorphine (BUP), called norbuprenorphine (NorBUP), is implicated in neonatal opioid withdrawal syndrome when BUP taken during pregnancy. Therefore, reducing or eliminating metabolism to NorBUP a novel strategy that will likely lower total fetal exposure opioids and thus improve offspring outcomes. Precision deuteration alters pharmacokinetics drugs without altering pharmacodynamics. Here, we report the synthesis testing deuterated (BUP-D2). Methods:...

10.3389/fphar.2023.1123261 article EN cc-by Frontiers in Pharmacology 2023-05-09
Coming Soon ...